Unknown PHASE2 INTERVENTIONAL 1-arm NCT03502629

Clinical Trial in Chinese Patients of Relapsed and Refractory Peripheral T Cell Lymphoma (GB226)

A Phase II Clinical Study to Evaluate the Efficacy and Safety of GB226 for the Treatment of Chinese Population With Relapsed and Refractory Peripheral T Cell Lymphoma (PTCL)

Sponsor: Genor Biopharma Co., Ltd.

Conditions Peripheral T Cell Lymphoma

Interventions GB226

Updated 11 times since 2018 Last updated: Mar 2, 2021 Started: Jul 2, 2018 Primary completion: Aug 31, 2021 Completion: Dec 30, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Peripheral T Cell Lymphoma and is currently ongoing. Genor Biopharma Co., Ltd. leads this study, which shows 11 recorded versions since 2018 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

11 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Apr 2023 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
Apr 2021 — Apr 2023 [monthly]

Recruiting PHASE2
Jan 2021 — Apr 2021 [monthly]

Recruiting PHASE2

▶ Show 6 earlier versions

Jul 2020 — Jan 2021 [monthly]

Recruiting PHASE2
Jan 2020 — Jul 2020 [monthly]

Recruiting PHASE2
Dec 2019 — Jan 2020 [monthly]

Recruiting PHASE2
Sep 2018 — Dec 2019 [monthly]

Recruiting PHASE2
Jun 2018 — Sep 2018 [monthly]

Recruiting PHASE2
May 2018 — Jun 2018 [monthly]

Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Genor Biopharma Co., Ltd.

Data source: Genor Biopharma Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China